Sarepta Therapeutics Inc. (S1RP34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 5.000 |
|---|---|
| 52-week range | 3.750 – 6.650 |
| Return, 1 month / 3 months | +3.3% / +19.3% |
| Return, 1 year / 3 years | −21.3% / – |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 78.6% |
| Worst drawdown (1 year) | -41.6% |
| Average daily value traded | 0.01M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sarepta Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on treatments for rare neuromuscular diseases. Its main work centres on therapies for Duchenne muscular dystrophy, including exon-skipping medicines and a gene therapy designed to deliver a working version of the dystrophin gene. The company also develops treatments for other rare muscle and central nervous system conditions. Its customers are mainly patients, clinicians and healthcare systems that treat people with these serious genetic disorders.
Sarepta Therapeutics Inc. is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code S1RP34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sarepta Therapeutics Inc. (S1RP34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 5.000 on 27 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 1,087 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.3% and over the last three months it rose 19.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 3.5% | ||
| From 52-week high | -22.1% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 19.3% | ||
| 6-month return | -4.4% | ||
| 12-month return, skipping the last month | -23.8% | ||
| Stability (higher is calmer) | 19 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 78.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.6% | ||
| Liquidity | 37 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M BRL | ||
| Zero-volume days | 8.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.3% |
|---|---|
| 1 month | +3.3% |
| 3 months | +19.3% |
| 6 months | −4.4% |
| 1 year | −21.3% |
| 3 years | – |
| 5 years | −77.8% |
Signals
| 50-day / 200-day average | 4.972 / 4.829 |
|---|---|
| Golden / death cross (60 days) | Golden, 12 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.209 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.